Innovative Diagnostic Solutions ANGLE's flagship Parsortix system offers cutting-edge circulating tumor cell (CTC) harvesting technology with FDA clearance, providing opportunities to collaborate on advanced diagnostic and research applications in oncology and drug development.

Diverse Revenue Streams With a focus on both diagnostic products and clinical services, ANGLE presents multiple pathways for expanding sales—ranging from consumables and devices to laboratory testing, enabling tailored solutions for pharmaceutical and research clients.

Expanding Market Presence ANGLE's international operations in the UK and US GCP-compliant laboratories position it well for global growth, offering potential for partnerships and sales expansion across multiple regions in the clinical and biotech sectors.

Strong Scientific Validation Over 80 peer-reviewed publications validate the performance of ANGLE's technology, providing credibility and a solid foundation for engaging institutions and researchers interested in innovative cancer diagnostics.

Solid Financial Position With revenues estimated between 50 and 100 million dollars and recent funding of 12 million dollars, ANGLE has the financial resources to invest in new product development and strategic sales initiatives targeting the biotech and pharmaceutical industries.